Our mission is to develop cannabinoid-based medicines that improve patients’ lives. Scientific literature indicates that cannabinoids represent a promising pharmaceutical class which has been insufficiently explored so far. Our mission is to further investigate the therapeutic potential of cannabinoids with the aim to develop medicines for various diseases and/or disorders for which the currently available therapeutic options are often suboptimal. Cannovex envisages to set up clinical studies to provide Proofs of Concept, to be followed by end-stage clinical trials in partnership with pharmaceutical companies, to evidence the safety and efficacy of the selected cannabinoid drug candidates and subsequently apply for market authorisation with European Medicines Agency (EMA) and the Food and Drug Administration (FDA) , thus paving the path to the market.